Author
Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.
14 papers
Recent·Most cited
H. Boutzen, A. Murison, J. C. Y. Wang, C. Arlidge, M. Lupien, K. B. Kaufmann, J. E. Dick
The paper identifies two distinct leukemia stem cell subtypes with unique transcriptional, epigenetic, and functional properties using a patient-derived cell model and single-cell analysis.
bioRxiv · Feb 9, 2024Cancer Biology
A. G. X. Zeng, I. Iacobucci, S. Shah, A. Mitchell, G. Wong, S. Bansal, D. Chen, Q. Gao, H. Kim, J. A. Kennedy, M. D. Minden, T. Haferlach, C. G. Mullighan, J. E. Dick
The paper constructs a reference atlas of human hematopoiesis and maps AML differentiation patterns, revealing genetic and non-genetic factors driving aberrant differentiation in leukemia.
bioRxiv · Dec 26, 2023Cancer Biology
I. Iacobucci, A. G. X. Zeng, Q. Gao, L. Garcia-Prat, P. Baviskar, S. Shah, A. J. Murison, V. Voisin, M. Chan-Seng-Yue, C. Cheng, C. Qu, C. Bailey, M. Lear, M. Witkowski, X. Zhou, , C. G. Mullighan
This study uses scRNA-seq to analyze B-ALL samples, revealing transcriptional heterogeneity and developmental origins, with specific subtypes associated with distinct cell populations and clinical outcomes.
bioRxiv · Dec 4, 2023Cancer Biology
N. A. Jakobsen, S. Turkalj, A. G. X. Zeng, B. Stoilova, M. Metzner, M. S. Nagree, S. Shah, R. Moore, B. Usukhbayar, M. A. Salazar, G.-A. Gafencu, A. Kennedy, S. Newman, B. J. L. Kendrick, A. H. Taylor, , P. Vyas
This study identifies how DNMT3A and TET2 mutations in hematopoietic stem cells confer a selective advantage by reducing inflammation and aging effects.
bioRxiv · Sep 12, 2023 · PreprintCancer Biology
A. G. X. Zeng, M. S. Nagree, N. A. Jakobsen, S. Shah, A. Murison, J.-G. Cheong, S. Turkalj, I. Lim, L. Jin, J. Araujo, A. G. Aguilar-Navarro, D. Parris, J. McLeod, H. Kim, H. S. Lee, , S. Z. Xie
The paper identifies a human HSC subset with inflammatory memory that accumulates with age and clonal hematopoiesis, potentially increasing cancer and infection risks.
bioRxiv · Sep 11, 2023 · PreprintCell Biology
T. Itkin, S. Houghton, R. Schreiner, Y. Lin, C. Badwe, V. Voisin, A. Murison, N. Seyedhassantehrani, K. B. Kaufmann, L. Garcia-Prat, G. T. Booth, F. Geng, Y. Liu, J. M. Gomez-Salinero, J.-H. Shieh, , S. Rafii
The paper identifies Fli-1's role in regulating HSC activation during regenerative hematopoiesis by enabling niche signaling and functional recovery.
bioRxiv · Mar 27, 2023 · PreprintCell Biology
C. S. Johnson, K. Sham, S. Belluschi, X. Wang, W. Lau, K. B. Kaufmann, G. Krivdova, E. F. Calderbank, N. Mende, J. McLeod, G. Mantica, M. J. Williams, C. Grey-Wilson, M. Drakopoulos, S. Sinha, , E. Laurenti
This study shows that human LT-HSC loss of repopulation capacity during ex vivo culture occurs rapidly after adaptation, independent of cell cycle progression.
bioRxiv · Nov 17, 2022 · PreprintCell Biology
L. D. Boila, S. Ghosh, S. K. Bandyopadhyay, L. Jin, A. Murison, A. G. X. Zeng, W. Shaikh, S. Bhowmik, S. S. N. A. Muddineni, M. Biswas, S. Sinha, S. S. Chatterjee, N. Mbong, O. I. Gan, A. Bose, , A. Sengupta
This study shows that KDM6A loss in AML increases sensitivity to PARP and BCL2 inhibitors, suggesting a new combination therapy approach for KDM6A-mutant AML.
bioRxiv · Jul 12, 2022 · PreprintCancer Biology
A. Vujovic, L. P. M. H. de Rooij, A. Keyvani Chahi, H. T. Chen, B. Yee, S. K. Loganathan, L. Liu, D. C. H. Chan, A. Tajik, E. Tsao, S. Moreira, P. Joshi, J. Xu, N. Wong, S. Zandi, , K. J. Hope
This study identifies RNA binding proteins essential for leukemic stem cell survival using an in vivo CRISPR screen and highlights ELAVL1 as a therapeutic target in AML.
bioRxiv · Jun 11, 2022 · PreprintCancer Biology
A. G. X. Zeng, S. Bansal, L. Jin, A. Mitchell, W. C. Chen, H. A. Abbas, M. Chan-Seng-Yue, V. Voisin, P. van Galen, A. Tierens, M. Cheok, C. Preudhomme, H. Dombret, N. Daver, P. A. Futreal, , J. E. Dick
This study identifies a cellular hierarchy framework in AML that links disease heterogeneity with drug response and develops a 7-gene biomarker predictive of drug sensitivity.
bioRxiv · Jan 25, 2022Cancer Biology
G. Krivdova, V. Voisin, E. M. Schoof, S. A. Marhon, A. J. Murison, J. L. McLeod, M. Gabra, A. G. Zeng, E. L. Van Nostrand, S. J. Aigner, A. A. Shishkin, B. A. Yee, K. G. Hermans, A. G. Trotman-Grant, N. Mbong, , E. R. Lechman
This study identifies miR-130a as a regulator of HSC self-renewal and differentiation, with TBL1XR1 as a key target, and shows its role in maintaining the oncogenic program in t(8;21) AML.
bioRxiv · Jul 30, 2021Cell Biology
J. F. Woolley, K. Chen, G. T. Saffi, G. E. Genc, D. K. C. Lee, I. Dzneladze, R. He, J. T.-S. Chow, M. M. Gabra, M. H. Son, C. M. P. Melo, C. A. Newell, A. He, E. M. Schoof, S. Z. Xie, , L. Salmena
This study identifies INPP4B's role in promoting leukemic stem cell (LSC) survival by enhancing lysosome biogenesis, leading to poor AML prognosis and suggesting therapeutic targets.
bioRxiv · Mar 25, 2021 · PreprintCancer Biology
L. Garcia-Prat, K. B. Kaufmann, F. Schneiter, V. Voisin, A. Murison, J. Chen, M. Chan-Seng-Yue, O. I. Gan, J. L. McLeod, S. A. Smith, M. C. Shoong, D. Parris, K. Pan, A. G. X. Zeng, G. Krivdova, , J. E. Dick
This study shows that lysosomes are regulated by TFEB and MYC to balance catabolic and anabolic processes in hematopoietic stem cells, influencing their fate and activation.
bioRxiv · Feb 24, 2021 · PreprintCell Biology
E. Wagenblast, J. Araujo, O. I. Gan, S. K. Cutting, A. Murison, G. Krivdova, M. Azkanaz, J. L. McLeod, S. A. Smith, S. A. Marhon, M. Gabra, M. Chan-Seng-Yue, L. Garcia-Prat, L. Salmena, D. D. D. De Carvalho, , E. R. Lechman
This study identifies the cellular origin and mechanisms of leukemia predisposition in Down syndrome by analyzing gene mutations and their effects in fetal hematopoietic cells.
bioRxiv · Nov 29, 2020Cancer Biology